Equities research analysts forecast that CryoPort Inc (NASDAQ:CYRX) will post sales of $3.67 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for CryoPort’s earnings, with the lowest sales estimate coming in at $3.40 million and the highest estimate coming in at $3.93 million. CryoPort reported sales of $2.71 million in the same quarter last year, which indicates a positive year-over-year growth rate of 35.4%. The business is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that CryoPort will report full year sales of $3.67 million for the current year, with estimates ranging from $18.00 million to $21.39 million. For the next financial year, analysts anticipate that the firm will post sales of $37.93 million per share, with estimates ranging from $36.62 million to $40.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for CryoPort.
CryoPort (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 6th. The consumer goods maker reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The firm had revenue of $3.33 million during the quarter, compared to the consensus estimate of $3.37 million. CryoPort had a negative return on equity of 47.36% and a negative net margin of 66.09%. The firm’s quarterly revenue was up 49.5% on a year-over-year basis.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its holdings in shares of CryoPort by 105.0% during the 2nd quarter. Northern Trust Corp now owns 22,179 shares of the consumer goods maker’s stock valued at $109,000 after purchasing an additional 11,358 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of CryoPort during the 3rd quarter valued at about $118,000. Bank of Montreal Can bought a new position in shares of CryoPort during the 4th quarter valued at about $142,000. Goldman Sachs Group Inc. bought a new position in shares of CryoPort during the 4th quarter valued at about $155,000. Finally, Monashee Investment Management LLC bought a new position in shares of CryoPort during the 4th quarter valued at about $192,000. 22.83% of the stock is owned by institutional investors and hedge funds.
CryoPort (NASDAQ CYRX) opened at $10.08 on Wednesday. The firm has a market cap of $253.84, a price-to-earnings ratio of -28.80 and a beta of -0.03. CryoPort has a 1-year low of $1.96 and a 1-year high of $10.40.
ILLEGAL ACTIVITY WARNING: This report was published by Week Herald and is owned by of Week Herald. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://weekherald.com/2018/03/14/cryoport-inc-cyrx-expected-to-announce-quarterly-sales-of-3-67-million.html.
CryoPort Company Profile
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.